ProCE Banner Activity

Novel Targeted Therapies in Relapsed/Refractory Follicular Lymphoma: Experts Answer Frequently Asked Questions

Clinical Thought

Read expert answers to questions about the latest therapies for the management of R/R FL in the third-line setting and beyond asked by the audience during a live symposium.

Released: January 29, 2024

Share

Faculty

Peter Martin

Peter Martin, MD

Professor of Medicine
Weill Cornell Medicine
New York, New York

Sonali M. Smith

Sonali M. Smith, MD, FASCO

Elwood V. Jensen Professor of Medicine
Chief, Section of Hematology/Oncology
Co-Leader, Cancer Service Line
The University of Chicago
Chicago, Illinois

Julie M. Vose

Julie M. Vose, MD, MBA

Payne Presidential Chair
Chief, Division of Hematology/Oncology
University of Nebraska Medical Center
Buffett Cancer Center
Omaha, Nebraska

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Genentech, a member of the Roche Group; Genmab; Ipsen Biopharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc.

Genentech, a member of the Roche Group

Genmab

Ipsen Biopharmaceuticals Inc

Regeneron Pharmaceuticals, Inc

Faculty Disclosure

Primary Author

Peter Martin, MD

Professor of Medicine
Weill Cornell Medicine
New York, New York

Peter Martin, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Beigene, Daiichi Sankyo, Genentech, Janssen, Merck, PeproMene.

Sonali M. Smith, MD, FASCO

Elwood V. Jensen Professor of Medicine
Chief, Section of Hematology/Oncology
Co-Leader, Cancer Service Line
The University of Chicago
Chicago, Illinois

Sonali M. Smith, MD, FASCO: consultant/advisor/speaker: Bristol Myers Squibb, Gilead, Ono Pharmaceutical. 

Julie M. Vose, MD, MBA

Payne Presidential Chair
Chief, Division of Hematology/Oncology
University of Nebraska Medical Center
Buffett Cancer Center
Omaha, Nebraska

Julie M. Vose, MD, MBA: consultant/advisor/speaker: AbbVie, Genmab, MEI Pharma; researcher: Epizyme, Kite, Loxo, Novartis.